PROM1 and colorectal cancer: Furthermore, the presence of CD133 has been correlated with resistance to chemotherapy in multiple cancer types, including 5-FU resistance in colorectal cancer, hepatocellular carcinoma, and glioblastoma multiforme (117–119).